2,0
19 mei 2026
Voormalige werknemer, meer dan 3 jaar
Poona
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht
Pluspunten
Good infrastructure in R&D, manufacturing, robust compliance set up.
Minpunten
Compared to Pharma biologics seems weak. Long timelines from inception to market delivery. In comparison, other Indian biosimilar sponsors have gone far ahead.